1072.3000 -7.00 (-0.65%)
NSE Aug 06, 2025 15:51 PM
Volume: 1.8M
 

Way2Wealth
Aurobindo Pharma consolidated revenue from operation grew 15.5% on a YoY basis to `4250.27 Crs. in Q1. Growth has been aided by API segment, US, and Europe formulation business segments. However, the ARV business contracted 36% on YoY basis due to weak...
Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
More from Aurobindo Pharma Ltd.
Recommended